Patients with SUFU mutations have a 20-fold higher risk of developing medulloblastoma (33%) than patients with PTCH1 mutations in Gorlin syndrome (<2%) [26–28]. Here, PTCH1 is linked to nevoid basal cell carcinoma syndrome.